{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T16:29:45Z","timestamp":1790872185388,"version":"4.1.0"},"reference-count":77,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T00:00:00Z","timestamp":1737331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T00:00:00Z","timestamp":1737331200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hypertens Res"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1038\/s41440-025-02110-5","type":"journal-article","created":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T06:46:05Z","timestamp":1737355565000},"page":"1458-1470","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Soluble guanylate cyclase stimulators and activators as potential antihypertensive drugs"],"prefix":"10.1038","volume":"48","author":[{"given":"Masashi","family":"Tawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keisuke","family":"Nakagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mamoru","family":"Ohkita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,20]]},"reference":[{"key":"2110_CR1","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.pharmthera.2005.09.002","volume":"111","author":"G Cohuet","year":"2006","unstructured":"Cohuet G, Struijker-Boudier H. Mechanisms of target organ damage caused by hypertension: therapeutic potential. Pharmacol Ther. 2006;111:81\u201398. https:\/\/doi.org\/10.1016\/j.pharmthera.2005.09.002","journal-title":"Pharmacol Ther"},{"key":"2110_CR2","unstructured":"Guideline for the pharmacological treatment of hypertension in adults. Geneva: World Health Organization; 2021."},{"key":"2110_CR3","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.ejim.2023.06.008","volume":"115","author":"M Kanbay","year":"2023","unstructured":"Kanbay M, Copur S, Tanriover C, Ucku D, Laffin L. Future treatments in hypertension: Can we meet the unmet needs of patients? Eur J Intern Med. 2023;115:18\u201328. https:\/\/doi.org\/10.1016\/j.ejim.2023.06.008","journal-title":"Eur J Intern Med"},{"key":"2110_CR4","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/S0031-6997(24)01457-1","volume":"52","author":"KA Lucas","year":"2000","unstructured":"Lucas KA, Pitari GM, Kazerounian S, Ruiz-Stewart I, Park J, Schulz S, et al. Guanylyl cyclases and signaling by cyclic GMP. Pharmacol Rev. 2000;52:375\u2013414.\u00a0https:\/\/doi.org\/10.1016\/S0031-6997(24)01457-1","journal-title":"Pharmacol Rev"},{"key":"2110_CR5","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1038\/hr.2011.39","volume":"34","author":"E Schulz","year":"2011","unstructured":"Schulz E, Gori T, M\u00fcnzel T. Oxidative stress and endothelial dysfunction in hypertension. Hypertens Res. 2011;34:665\u201373. https:\/\/doi.org\/10.1038\/hr.2011.39","journal-title":"Hypertens Res"},{"key":"2110_CR6","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1681\/ASN.V541057","volume":"5","author":"R MacAllister","year":"1994","unstructured":"MacAllister R, Vallance P. Nitric oxide in essential and renal hypertension. J Am Soc Nephrol. 1994;5:1057\u201365. https:\/\/doi.org\/10.1681\/ASN.V541057","journal-title":"J Am Soc Nephrol"},{"key":"2110_CR7","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1097\/HJH.0b013e328341d19e","volume":"29","author":"N Toda","year":"2011","unstructured":"Toda N, Arakawa K. Salt-induced hemodynamic regulation mediated by nitric oxide. J Hypertens. 2011;29:415\u201324. https:\/\/doi.org\/10.1097\/HJH.0b013e328341d19e","journal-title":"J Hypertens"},{"key":"2110_CR8","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1161\/HYPERTENSIONAHA.116.06778","volume":"67","author":"NW Rajapakse","year":"2016","unstructured":"Rajapakse NW, Head GA, Kaye DM. Say NO to Obesity-Related Hypertension: Role of the L-Arginine-Nitric Oxide Pathway. Hypertension. 2016;67:813\u20139. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.116.06778","journal-title":"Hypertension"},{"key":"2110_CR9","doi-asserted-by":"publisher","first-page":"2061","DOI":"10.1042\/CS20190851","volume":"133","author":"NW Rajapakse","year":"2019","unstructured":"Rajapakse NW, Giam B, Kuruppu S, Head GA, Kaye DM. Impaired l-arginine-nitric oxide pathway contributes to the pathogenesis of resistant hypertension. Clin Sci (Lond). 2019;133:2061\u20137. https:\/\/doi.org\/10.1042\/CS20190851","journal-title":"Clin Sci (Lond)"},{"key":"2110_CR10","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1038\/nrd4623","volume":"14","author":"JO Lundberg","year":"2015","unstructured":"Lundberg JO, Gladwin MT, Weitzberg E. Strategies to increase nitric oxide signalling in cardiovascular disease. Nat Rev Drug Discov. 2015;14:623\u201341. https:\/\/doi.org\/10.1038\/nrd4623","journal-title":"Nat Rev Drug Discov"},{"key":"2110_CR11","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1038\/nrd2038","volume":"5","author":"OV Evgenov","year":"2006","unstructured":"Evgenov OV, Pacher P, Schmidt PM, Hask\u00f3 G, Schmidt HH, Stasch JP. NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential. Nat Rev Drug Discov. 2006;5:755\u201368. https:\/\/doi.org\/10.1038\/nrd2038","journal-title":"Nat Rev Drug Discov"},{"key":"2110_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.vph.2022.107023","volume":"145","author":"M Tawa","year":"2022","unstructured":"Tawa M, Okamura T. Factors influencing the soluble guanylate cyclase heme redox state in blood vessels. Vascul Pharmacol. 2022;145:107023.\u00a0https:\/\/doi.org\/10.1016\/j.vph.2022.107023","journal-title":"Vascul Pharmacol"},{"key":"2110_CR13","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1007\/164_2018_197","volume":"264","author":"P Sandner","year":"2021","unstructured":"Sandner P, Zimmer DP, Milne GT, Follmann M, Hobbs A, Stasch JP. Soluble guanylate cyclase stimulators and activators. Handb Exp Pharmacol. 2021;264:355\u201394. https:\/\/doi.org\/10.1007\/164_2018_197","journal-title":"Handb Exp Pharmacol"},{"key":"2110_CR14","doi-asserted-by":"publisher","first-page":"4130","DOI":"10.1111\/bph.15698","volume":"181","author":"P Sandner","year":"2024","unstructured":"Sandner P, Follmann M, Becker-Pelster E, Hahn MG, Meier C, Freitas C, et al. Soluble GC stimulators and activators: Past, present and future. Br J Pharmacol. 2024;81:4130\u201351. https:\/\/doi.org\/10.1111\/bph.15698.","journal-title":"Br J Pharmacol"},{"key":"2110_CR15","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1124\/jpet.111.183400","volume":"339","author":"CN Joshi","year":"2011","unstructured":"Joshi CN, Martin DN, Fox JC, Mendelev NN, Brown TA, Tulis DA. The Soluble Guanylate Cyclase Stimulator BAY 41-2272 Inhibits Vascular Smooth Muscle Growth through the cAMP-Dependent Protein Kinase and cGMP-Dependent Protein Kinase Pathways. J Pharmacol Exp Ther. 2011;339:394\u2013402. https:\/\/doi.org\/10.1124\/jpet.111.183400","journal-title":"J Pharmacol Exp Ther"},{"key":"2110_CR16","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1016\/j.cellsig.2016.06.012","volume":"28","author":"AW Holt","year":"2016","unstructured":"Holt AW, Martin DN, Shaver PR, Adderley SP, Stone JD, Joshi CN, et al. Soluble guanylyl cyclase-activated cyclic GMP-dependent protein kinase inhibits arterial smooth muscle cell migration independent of VASP-Serine 239 phosphorylation. Cell Signal. 2016;28:1364\u201379. https:\/\/doi.org\/10.1016\/j.cellsig.2016.06.012","journal-title":"Cell Signal"},{"key":"2110_CR17","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2021.661171.","volume":"12","author":"YC Hung","year":"2021","unstructured":"Hung YC, Liu YC, Wu BN, Yeh JL, Hsu JH. Cinaciguat Prevents Postnatal Closure of Ductus Arteriosus by Vasodilation and Anti-remodeling in Neonatal Rats. Front Physiol. 2021;12:661171. https:\/\/doi.org\/10.3389\/fphys.2021.661171","journal-title":"Front Physiol"},{"key":"2110_CR18","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1111\/bph.15650","volume":"179","author":"HA Jama","year":"2022","unstructured":"Jama HA, Muralitharan RR, Xu C, O\u2019Donnell JA, Bertagnolli M, Broughton BRS, et al. Rodent models of hypertension. Br J Pharmacol. 2022;179:918\u201337. https:\/\/doi.org\/10.1111\/bph.15650","journal-title":"Br J Pharmacol"},{"key":"2110_CR19","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1038\/sj.bjp.0700982","volume":"120","author":"A M\u00fclsch","year":"1997","unstructured":"M\u00fclsch A, Bauersachs J, Sch\u00e4fer A, Stasch JP, Kast R, Busse R. Effect of YC-1, an NO-independent, superoxide-sensitive stimulator of soluble guanylyl cyclase, on smooth muscle responsiveness to nitrovasodilators. Br J Pharmacol. 1997;120:681\u20139. https:\/\/doi.org\/10.1038\/sj.bjp.0700982","journal-title":"Br J Pharmacol"},{"key":"2110_CR20","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1161\/01.res.85.6.534","volume":"85","author":"H Ruetten","year":"1999","unstructured":"Ruetten H, Zabel U, Linz W, Schmidt HH. Downregulation of soluble guanylyl cyclase in young and aging spontaneously hypertensive rats. Circ Res. 1999;85:534\u201341. https:\/\/doi.org\/10.1161\/01.res.85.6.534","journal-title":"Circ Res"},{"key":"2110_CR21","doi-asserted-by":"publisher","first-page":"3893","DOI":"10.1182\/blood-2002-08-2608","volume":"101","author":"JF Ndisang","year":"2003","unstructured":"Ndisang JF, Wu L, Zhao W, Wang R. Induction of heme oxygenase-1 and stimulation of cGMP production by hemin in aortic tissues from hypertensive rats. Blood. 2003;101:3893\u2013900. https:\/\/doi.org\/10.1182\/blood-2002-08-2608","journal-title":"Blood"},{"key":"2110_CR22","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/ajh.2009.18","volume":"22","author":"FB Priviero","year":"2009","unstructured":"Priviero FB, Zemse SM, Teixeira CE, Webb RC. Oxidative stress impairs vasorelaxation induced by the soluble guanylyl cyclase activator BAY 41-2272 in spontaneously hypertensive rats. Am J Hypertens. 2009;22:493\u20139. https:\/\/doi.org\/10.1038\/ajh.2009.18","journal-title":"Am J Hypertens"},{"key":"2110_CR23","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1038\/35065611","volume":"410","author":"JP Stasch","year":"2001","unstructured":"Stasch JP, Becker EM, Alonso-Alija C, Apeler H, Dembowsky K, Feurer A, et al. NO-independent regulatory site on soluble guanylate cyclase. Nature. 2001;410:212\u20135. https:\/\/doi.org\/10.1038\/35065611","journal-title":"Nature"},{"key":"2110_CR24","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1038\/sj.bjp.0704483","volume":"135","author":"JP Stasch","year":"2002","unstructured":"Stasch JP, Dembowsky K, Perzborn E, Stahl E, Schramm M. Cardiovascular actions of a novel NO-independent guanylyl cyclase stimulator, BAY 41-8543: in vivo studies. Br J Pharmacol. 2002;135:344\u201355. https:\/\/doi.org\/10.1038\/sj.bjp.0704483","journal-title":"Br J Pharmacol"},{"key":"2110_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2020.127574","volume":"30","author":"L Brockunier","year":"2020","unstructured":"Brockunier L, Stelmach J, Guo J, Spencer T, Rosauer K, Bansal A, et al. Soluble guanylate cyclase stimulators for the treatment of hypertension: Discovery of MK-2947. Bioorg Med Chem Lett. 2020;30:127574. https:\/\/doi.org\/10.1016\/j.bmcl.2020.127574","journal-title":"Bioorg Med Chem Lett"},{"key":"2110_CR26","doi-asserted-by":"publisher","first-page":"2500","DOI":"10.1111\/bph.16142","volume":"180","author":"F Wunder","year":"2023","unstructured":"Wunder F, Stasch JP, Knorr A, Mondritzki T, Brockschnieder D, Becker-Pelster EM, et al. Identification and characterization of the new generation sGC stimulator BAY-747 designed for the treatment of resistant hypertension. Br J Pharmacol. 2023;180:2500\u201313. https:\/\/doi.org\/10.1111\/bph.16142","journal-title":"Br J Pharmacol"},{"key":"2110_CR27","doi-asserted-by":"publisher","first-page":"419","DOI":"10.3389\/fphar.2020.00419","volume":"11","author":"DP Zimmer","year":"2020","unstructured":"Zimmer DP, Shea CM, Tobin JV, Tchernychev B, Germano P, Sykes K, et al. Olinciguat, an Oral sGC Stimulator, Exhibits Diverse Pharmacology Across Preclinical Models of Cardiovascular, Metabolic, Renal, and Inflammatory Disease. Front Pharmacol. 2020;11:419. https:\/\/doi.org\/10.3389\/fphar.2020.00419","journal-title":"Front Pharmacol"},{"key":"2110_CR28","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1124\/jpet.117.247429","volume":"365","author":"JV Tobin","year":"2018","unstructured":"Tobin JV, Zimmer DP, Shea C, Germano P, Bernier SG, Liu G, et al. Pharmacological Characterization of IW-1973, a Novel Soluble Guanylate Cyclase Stimulator with Extensive Tissue Distribution, Antihypertensive, Anti-Inflammatory, and Antifibrotic Effects in Preclinical Models of Disease. J Pharmacol Exp Ther. 2018;365:664\u201375. https:\/\/doi.org\/10.1124\/jpet.117.247429","journal-title":"J Pharmacol Exp Ther"},{"issue":"Suppl 1","key":"2110_CR29","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2210-9-S1-P29","volume":"9","author":"ES Jones","year":"2009","unstructured":"Jones ES, Kemp-Harper BK, Stasch JP, Schmidt HHHW, Widdop RE. Cardioprotective effects in aged spontaneously hypertensive rats due to chronic stimulation\/activation of sGC without hypotension. BMC Pharmacol. 2009;9:P29. https:\/\/doi.org\/10.1186\/1471-2210-9-S1-P29","journal-title":"BMC Pharmacol"},{"key":"2110_CR30","doi-asserted-by":"publisher","first-page":"2552","DOI":"10.1172\/JCI28371","volume":"116","author":"JP Stasch","year":"2006","unstructured":"Stasch JP, Schmidt PM, Nedvetsky PI, Nedvetskaya TY, H S AK, Meurer S, et al. Targeting the heme-oxidized nitric oxide receptor for selective vasodilatation of diseased blood vessels. J Clin Invest. 2006;116:2552\u201361. https:\/\/doi.org\/10.1172\/JCI28371","journal-title":"J Clin Invest"},{"key":"2110_CR31","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1038\/sj.bjp.0704778","volume":"136","author":"JP Stasch","year":"2002","unstructured":"Stasch JP, Schmidt P, Alonso-Alija C, Apeler H, Dembowsky K, Haerter M, et al. NO- and haem-independent activation of soluble guanylyl cyclase: molecular basis and cardiovascular implications of a new pharmacological principle. Br J Pharmacol. 2002;136:773\u201383. https:\/\/doi.org\/10.1038\/sj.bjp.0704778","journal-title":"Br J Pharmacol"},{"key":"2110_CR32","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1055\/s-0031-1296471","volume":"58","author":"A Knorr","year":"2008","unstructured":"Knorr A, Hirth-Dietrich C, Alonso-Alija C, H\u00e4rter M, Hahn M, Keim Y, et al. Nitric oxide-independent activation of soluble guanylate cyclase by BAY 60-2770 in experimental liver fibrosis. Arzneimittelforschung. 2008;58:71\u201380. https:\/\/doi.org\/10.1055\/s-0031-1296471","journal-title":"Arzneimittelforschung"},{"key":"2110_CR33","doi-asserted-by":"publisher","first-page":"5323","DOI":"10.1021\/acs.jmedchem.0c02154","volume":"64","author":"MG Hahn","year":"2021","unstructured":"Hahn MG, Lampe T, El Sheikh S, Griebenow N, Woltering E, Schlemmer KH, et al. Discovery of the Soluble Guanylate Cyclase Activator Runcaciguat (BAY 1101042). J Med Chem. 2021;64:5323\u201344. https:\/\/doi.org\/10.1021\/acs.jmedchem.0c02154","journal-title":"J Med Chem"},{"key":"2110_CR34","doi-asserted-by":"publisher","DOI":"10.1111\/micc.12298","volume":"24","author":"M Mancini","year":"2017","unstructured":"Mancini M, Scavone A, Sartorio CL, Baccaro R, Kleinert C, Pernazza A, et al. PG. Effect of different drug classes on reverse remodeling of intramural coronary arterioles in the spontaneously hypertensive rat. Microcirculation. 2017;24:e12298. https:\/\/doi.org\/10.1111\/micc.12298","journal-title":"Microcirculation"},{"issue":"Suppl 1","key":"2110_CR35","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2210-5-S1-S19","volume":"5","author":"U Schindler","year":"2005","unstructured":"Schindler U, Klein M, Linz W, R\u00fctten H, Sch\u00e4fer S, Strobel H, et al. Role of activators of ferric sGC in cardiovascular disease. BMC Pharmacol. 2005;5:S19. https:\/\/doi.org\/10.1186\/1471-2210-5-S1-S19","journal-title":"BMC Pharmacol"},{"key":"2110_CR36","doi-asserted-by":"publisher","first-page":"e21853","DOI":"10.1371\/journal.pone.0021853","volume":"6","author":"S Geschka","year":"2011","unstructured":"Geschka S, Kretschmer A, Sharkovska Y, Evgenov OV, Lawrenz B, Hucke A, et al. Soluble guanylate cyclase stimulation prevents fibrotic tissue remodeling and improves survival in salt-sensitive Dahl rats. PLoS One. 2011;6:e21853. https:\/\/doi.org\/10.1371\/journal.pone.0021853","journal-title":"PLoS One"},{"key":"2110_CR37","doi-asserted-by":"publisher","first-page":"F148","DOI":"10.1152\/ajprenal.00247.2019","volume":"318","author":"CM Shea","year":"2020","unstructured":"Shea CM, Price GM, Liu G, Sarno R, Buys ES, Currie MG, et al. Soluble guanylate cyclase stimulator praliciguat attenuates inflammation, fibrosis, and end-organ damage in the Dahl model of cardiorenal failure. Am J Physiol Renal Physiol. 2020;318:F148\u2013F159. https:\/\/doi.org\/10.1152\/ajprenal.00247.2019","journal-title":"Am J Physiol Renal Physiol"},{"key":"2110_CR38","doi-asserted-by":"publisher","first-page":"e0145048.","DOI":"10.1371\/journal.pone.0145048","volume":"10","author":"LS Hoffmann","year":"2015","unstructured":"Hoffmann LS, Kretschmer A, Lawrenz B, Hocher B, Stasch JP. Chronic Activation of Heme Free Guanylate Cyclase Leads to Renal Protection in Dahl Salt-Sensitive Rats. PLoS One. 2015;10:e0145048. https:\/\/doi.org\/10.1371\/journal.pone.0145048","journal-title":"PLoS One"},{"key":"2110_CR39","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1038\/sj.bjp.0703320","volume":"130","author":"L Rothermund","year":"2000","unstructured":"Rothermund L, Friebe A, Paul M, Koesling D, Kreutz R. Acute blood pressure effects of YC-1-induced activation of soluble guanylyl cyclase in normotensive and hypertensive rats. Br J Pharmacol. 2000;130:205\u20138. https:\/\/doi.org\/10.1038\/sj.bjp.0703320","journal-title":"Br J Pharmacol"},{"key":"2110_CR40","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1097\/01.fjc.0000210071.54828.9b","volume":"47","author":"M Zanfolin","year":"2006","unstructured":"Zanfolin M, Faro R, Araujo EG, Guaraldo AM, Antunes E, De Nucci G. Protective effects of BAY 41-2272 (sGC stimulator) on hypertension, heart, and cardiomyocyte hypertrophy induced by chronic L-NAME treatment in rats. J Cardiovasc Pharmacol. 2006;47:391\u20135. https:\/\/doi.org\/fjc.0000210071.54828.9b","journal-title":"J Cardiovasc Pharmacol"},{"key":"2110_CR41","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-01392-1","volume":"7","author":"C Rippe","year":"2017","unstructured":"Rippe C, Zhu B, Krawczyk KK, Bavel EV, Albinsson S, Sj\u00f6lund J, et al. Hypertension reduces soluble guanylyl cyclase expression in the mouse aorta via the Notch signaling pathway. Sci Rep. 2017;7:1334. https:\/\/doi.org\/10.1038\/s41598-017-01392-1","journal-title":"Sci Rep"},{"key":"2110_CR42","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1161\/01.HYP.0000241087.12492.47","volume":"48","author":"H Masuyama","year":"2006","unstructured":"Masuyama H, Tsuruda T, Kato J, Imamura T, Asada Y, Stasch JP, et al. Soluble guanylate cyclase stimulation on cardiovascular remodeling in angiotensin II-induced hypertensive rats. Hypertension. 2006;48:972\u20138. https:\/\/doi.org\/10.1161\/01.HYP.0000241087.12492.47","journal-title":"Hypertension"},{"key":"2110_CR43","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.129183","volume":"4","author":"BG Durgin","year":"2019","unstructured":"Durgin BG, Hahn SA, Schmidt HM, Miller MP, Hafeez N, Mathar I, et al. Loss of smooth muscle CYB5R3 amplifies angiotensin II-induced hypertension by increasing sGC heme oxidation. JCI Insight. 2019;4:e129183. https:\/\/doi.org\/10.1172\/jci.insight.129183","journal-title":"JCI Insight"},{"key":"2110_CR44","doi-asserted-by":"publisher","first-page":"2363","DOI":"10.1007\/s00210-021-02149-4","volume":"394","author":"A B\u00e9nardeau","year":"2021","unstructured":"B\u00e9nardeau A, Kahnert A, Schomber T, Meyer J, Pavkovic M, Kretschmer A, et al. Runcaciguat, a novel soluble guanylate cyclase activator, shows renoprotection in hypertensive, diabetic, and metabolic preclinical models of chronic kidney disease. Naunyn Schmiedebergs Arch Pharmacol. 2021;394:2363\u201379. https:\/\/doi.org\/10.1007\/s00210-021-02149-4","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"2110_CR45","doi-asserted-by":"publisher","first-page":"e87","DOI":"10.1161\/HYP.0000000000000090","volume":"73","author":"LO Lerman","year":"2019","unstructured":"Lerman LO, Kurtz TW, Touyz RM, Ellison DH, Chade AR, Crowley SD, et al. Animal Models of Hypertension: A Scientific Statement From the American Heart Association. Hypertension. 2019;73:e87\u2013e120. https:\/\/doi.org\/10.1161\/HYP.0000000000000090","journal-title":"Hypertension"},{"key":"2110_CR46","doi-asserted-by":"publisher","first-page":"3757","DOI":"10.1007\/s00210-023-02561-y","volume":"396","author":"O Gawrys","year":"2023","unstructured":"Gawrys O, Huskov\u00e1 Z, \u0160karoupkov\u00e1 P, Honetschl\u00e4gerov\u00e1 Z, Va\u0148ourkov\u00e1 Z, Kikerlov\u00e1 S, et al. The treatment with sGC stimulator improves survival of hypertensive rats in response to volume-overload induced by aorto-caval fistula. Naunyn Schmiedebergs Arch Pharmacol. 2023;396:3757\u201373. https:\/\/doi.org\/10.1007\/s00210-023-02561-y","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"2110_CR47","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.96006","volume":"3","author":"N Wilck","year":"2018","unstructured":"Wilck N, Mark\u00f3 L, Balogh A, Kr\u00e4ker K, Herse F, Bartolomaeus H, et al. Nitric oxide-sensitive guanylyl cyclase stimulation improves experimental heart failure with preserved ejection fraction. JCI Insight. 2018;3:e96006. https:\/\/doi.org\/10.1172\/jci.insight.96006","journal-title":"JCI Insight"},{"key":"2110_CR48","doi-asserted-by":"publisher","first-page":"1666","DOI":"10.1097\/HJH.0b013e32833b558c","volume":"28","author":"Y Sharkovska","year":"2010","unstructured":"Sharkovska Y, Kalk P, Lawrenz B, Godes M, Hoffmann LS, Wellkisch K, et al. Nitric oxide-independent stimulation of soluble guanylate cyclase reduces organ damage in experimental low-renin and high-renin models. J Hypertens. 2010;28:1666\u201375. https:\/\/doi.org\/10.1097\/HJH.0b013e32833b558c","journal-title":"J Hypertens"},{"key":"2110_CR49","doi-asserted-by":"publisher","first-page":"5146","DOI":"10.1021\/acs.jmedchem.7b00449","volume":"60","author":"M Follmann","year":"2017","unstructured":"Follmann M, Ackerstaff J, Redlich G, Wunder F, Lang D, Kern A, et al. Discovery of the Soluble Guanylate Cyclase Stimulator Vericiguat (BAY 1021189) for the Treatment of Chronic Heart Failure. J Med Chem. 2017;60:5146\u201361. https:\/\/doi.org\/10.1021\/acs.jmedchem.7b00449","journal-title":"J Med Chem"},{"key":"2110_CR50","doi-asserted-by":"publisher","first-page":"7280","DOI":"10.1021\/acs.jmedchem.2c02082","volume":"66","author":"A Vakalopoulos","year":"2023","unstructured":"Vakalopoulos A, Wunder F, Hartung IV, Redlich G, Jautelat R, Buchgraber P. et al. New Generation of sGC Stimulators: Discovery of Imidazo[1,2- a]pyridine Carboxamide BAY 1165747 (BAY-747), a Long-Acting Soluble Guanylate Cyclase Stimulator for the Treatment of Resistant Hypertension. J Med Chem. 2023;66:7280\u2013303. https:\/\/doi.org\/10.1021\/acs.jmedchem.2c02082.","journal-title":"J Med Chem"},{"key":"2110_CR51","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2021.173978","volume":"899","author":"Y Doghri","year":"2021","unstructured":"Doghri Y, Dubreil L, Lalanne V, H\u00e9lissen O, Fleurisson R, Thorin C, et al. Soluble guanylate cyclase chronic stimulation effects on cardiovascular reactivity in cafeteria diet-induced rat model of metabolic syndrome. Eur J Pharmacol. 2021;899:173978. https:\/\/doi.org\/10.1016\/j.ejphar.2021.173978","journal-title":"Eur J Pharmacol"},{"key":"2110_CR52","doi-asserted-by":"publisher","first-page":"H523","DOI":"10.1152\/ajpheart.00386.2021","volume":"322","author":"V Reverte","year":"2022","unstructured":"Reverte V, Rodriguez F, Oltra L, Moreno JM, Llin\u00e1s MT, Shea CM, et al. SGLT2 inhibition potentiates the cardiovascular, renal, and metabolic effects of sGC stimulation in hypertensive rats with prolonged exposure to high-fat diet. Am J Physiol Heart Circ Physiol. 2022;322:H523\u2013H536. https:\/\/doi.org\/10.1152\/ajpheart.00386.2021","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"2110_CR53","doi-asserted-by":"publisher","first-page":"e0261000","DOI":"10.1371\/journal.pone.0261000","volume":"17","author":"L Hu","year":"2022","unstructured":"Hu L, Chen Y, Zhou X, Hoek M, Cox J, Lin K, et al. Effects of soluble guanylate cyclase stimulator on renal function in ZSF-1 model of diabetic nephropathy. PLoS One. 2022;17:e0261000. https:\/\/doi.org\/10.1371\/journal.pone.0261000","journal-title":"PLoS One"},{"key":"2110_CR54","doi-asserted-by":"publisher","first-page":"128","DOI":"10.3389\/fphar.2012.00128","volume":"3","author":"MH Costell","year":"2012","unstructured":"Costell MH, Ancellin N, Bernard RE, Zhao S, Upson JJ, Morgan LA, et al. Comparison of soluble guanylate cyclase stimulators and activators in models of cardiovascular disease associated with oxidative stress. Front Pharmacol. 2012;3:128. https:\/\/doi.org\/10.3389\/fphar.2012.00128","journal-title":"Front Pharmacol"},{"key":"2110_CR55","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1124\/jpet.115.230706","volume":"356","author":"CM Boustany-Kari","year":"2016","unstructured":"Boustany-Kari CM, Harrison PC, Chen H, Lincoln KA, Qian HS, Clifford H, et al. A Soluble Guanylate Cyclase Activator Inhibits the Progression of Diabetic Nephropathy in the ZSF1 Rat. J Pharmacol Exp Ther. 2016;356:712\u20139. https:\/\/doi.org\/10.1124\/jpet.115.230706","journal-title":"J Pharmacol Exp Ther"},{"key":"2110_CR56","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1124\/jpet.122.001423","volume":"384","author":"GA Reinhart","year":"2023","unstructured":"Reinhart GA, Harrison PC, Lincoln K, Chen H, Sun P, Hill J, et al. The Novel, Clinical-Stage Soluble Guanylate Cyclase Activator BI 685509 Protects from Disease Progression in Models of Renal Injury and Disease. J Pharmacol Exp Ther. 2023;384:382\u201392. https:\/\/doi.org\/10.1124\/jpet.122.001423","journal-title":"J Pharmacol Exp Ther"},{"key":"2110_CR57","doi-asserted-by":"publisher","first-page":"e0146212.","DOI":"10.1371\/journal.pone.0146212","volume":"11","author":"IL Geenen","year":"2016","unstructured":"Geenen IL, Kolk FF, Molin DG, Wagenaar A, Compeer MG, Tordoir JH, et al. Nitric Oxide Resistance Reduces Arteriovenous Fistula Maturation in Chronic Kidney Disease in Rats. PLoS One. 2016;11:e0146212. https:\/\/doi.org\/10.1371\/journal.pone.0146212","journal-title":"PLoS One"},{"key":"2110_CR58","doi-asserted-by":"publisher","first-page":"1907","DOI":"10.1097\/HJH.0000000000000648","volume":"33","author":"B Stancu","year":"2015","unstructured":"Stancu B, Kr\u00e4mer S, Loof T, Mika A, Amann K, Neumayer HH, et al. Soluble guanylate cyclase stimulator BAY 41-8543 and female sex ameliorate uremic aortic remodeling in a rat model of mild uremia. J Hypertens. 2015;33:1907\u201320. https:\/\/doi.org\/10.1097\/HJH.0000000000000648","journal-title":"J Hypertens"},{"key":"2110_CR59","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1038\/sj.bjp.0706792","volume":"148","author":"P Kalk","year":"2006","unstructured":"Kalk P, Godes M, Relle K, Rothkegel C, Hucke A, Stasch JP, et al. NO-independent activation of soluble guanylate cyclase prevents disease progression in rats with 5\/6 nephrectomy. Br J Pharmacol. 2006;148:853\u20139. https:\/\/doi.org\/10.1038\/sj.bjp.0706792","journal-title":"Br J Pharmacol"},{"key":"2110_CR60","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1159\/000104091","volume":"30","author":"K Benz","year":"2007","unstructured":"Benz K, Orth SR, Simonaviciene A, Linz W, Schindler U, R\u00fctten H, et al. Blood pressure-independent effect of long-term treatment with the soluble heme-independent guanylyl cyclase activator HMR1766 on progression in a model of noninflammatory chronic renal damage. Kidney Blood Press Res. 2007;30:224\u201333. https:\/\/doi.org\/10.1159\/000104091","journal-title":"Kidney Blood Press Res"},{"key":"2110_CR61","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1159\/000520655","volume":"107","author":"M Tawa","year":"2022","unstructured":"Tawa M, Shimosato T, Nakagawa K, Okamura T, Ohkita M. Soluble Guanylate Cyclase-Mediated Relaxation in Aortas from Rats with Renovascular Hypertension. Pharmacology. 2022;107:235\u201340. https:\/\/doi.org\/10.1159\/000520655","journal-title":"Pharmacology"},{"key":"2110_CR62","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/j.molmed.2010.07.006","volume":"16","author":"PW Buehler","year":"2010","unstructured":"Buehler PW, D\u2019Agnillo F, Schaer DJ. Hemoglobin-based oxygen carriers: From mechanisms of toxicity and clearance to rational drug design. Trends Mol Med. 2010;16:447\u201357. https:\/\/doi.org\/10.1016\/j.molmed.2010.07.006","journal-title":"Trends Mol Med"},{"key":"2110_CR63","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1089\/ars.2013.5181","volume":"19","author":"NJ Raat","year":"2013","unstructured":"Raat NJ, Tabima DM, Specht PA, Tejero J, Champion HC, Kim-Shapiro DB, et al. Direct sGC activation bypasses NO scavenging reactions of intravascular free oxy-hemoglobin and limits vasoconstriction. Antioxid Redox Signal. 2013;19:2232\u201343. https:\/\/doi.org\/10.1089\/ars.2013.5181","journal-title":"Antioxid Redox Signal"},{"key":"2110_CR64","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1038\/ki.2011.288","volume":"80","author":"P Kandula","year":"2011","unstructured":"Kandula P, Agarwal R. Proteinuria and hypertension with tyrosine kinase inhibitors. Kidney Int. 2011;80:1271\u20137. https:\/\/doi.org\/10.1038\/ki.2011.288","journal-title":"Kidney Int"},{"key":"2110_CR65","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.118.009557","volume":"7","author":"J Witte","year":"2018","unstructured":"Witte J, M\u00fchlbauer M, Braun D, Steinbach A, Golchert J, Rettig R, et al. Renal Soluble Guanylate Cyclase Is Downregulated in Sunitinib-Induced Hypertension. J Am Heart Assoc. 2018;7:e009557. https:\/\/doi.org\/10.1161\/JAHA.118.009557","journal-title":"J Am Heart Assoc"},{"key":"2110_CR66","doi-asserted-by":"publisher","first-page":"1900","DOI":"10.1038\/s41440-023-01323-w","volume":"46","author":"K Bokuda","year":"2023","unstructured":"Bokuda K, Ichihara A. Preeclampsia up to date-What\u2019s going on? Hypertens Res. 2023;46:1900\u20137. https:\/\/doi.org\/10.1038\/s41440-023-01323-w","journal-title":"Hypertens Res"},{"issue":"Suppl","key":"2110_CR67","doi-asserted-by":"publisher","first-page":"S12","DOI":"10.1016\/j.ajog.2009.10.051","volume":"201","author":"A Ladaique","year":"2009","unstructured":"Ladaique A, Le Roch A, Storme L, Deruelle P. Maternal and fetal effects of bay 41-2272, a direct soluble guanylate cyclase activator, in a model of preeclampsia and intra uterine growth restriction. Am J Obstet Gynecol. 2009;201(Suppl):S12. https:\/\/doi.org\/10.1016\/j.ajog.2009.10.051","journal-title":"Am J Obstet Gynecol"},{"issue":"Suppl 1","key":"2110_CR68","doi-asserted-by":"publisher","first-page":"A013","DOI":"10.1161\/hyp.72.suppl_1.013","volume":"72","author":"BA Bakrania","year":"2018","unstructured":"Bakrania BA, Spradley FT, Travis AB, Sandner P, Granger JP. Soluble Guanylate Cyclase Activators Improve Vascular Function and Attenuate Placental Ischemia-Induced Hypertension. Hypertension. 2018;72(Suppl 1):A013. https:\/\/doi.org\/10.1161\/hyp.72.suppl_1.013","journal-title":"Hypertension"},{"key":"2110_CR69","doi-asserted-by":"publisher","first-page":"1568","DOI":"10.1038\/s41440-021-00748-5","volume":"44","author":"J Vogel","year":"2021","unstructured":"Vogel J, Boehme P, Homann S, Boehm M, Sch\u00fctt KA, Boden K, et al. sGC stimulation lowers elevated blood pressure in a new canine model of resistant hypertension. Hypertens Res. 2021;44:1568\u201377. https:\/\/doi.org\/10.1038\/s41440-021-00748-5","journal-title":"Hypertens Res"},{"key":"2110_CR70","unstructured":"Marquardt T, Follmann M, Stasch JP. Stimulators and\/or activators of soluble guanylate cyclase (sGC) in combination with an inhibitor of neutral endopeptidase (NEP inhibitor) and\/or an angiotensin AII antagonist and the use thereof. US Patent. 2021; US11166932B2"},{"key":"2110_CR71","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1177\/0091270008319793","volume":"48","author":"R Frey","year":"2008","unstructured":"Frey R, M\u00fcck W, Unger S, Artmeier-Brandt U, Weimann G, Wensing G. Single-dose pharmacokinetics, pharmacodynamics, tolerability, and safety of the soluble guanylate cyclase stimulator BAY 63-2521: an ascending-dose study in healthy male volunteers. J Clin Pharmacol. 2008;48:926\u201334. https:\/\/doi.org\/10.1177\/0091270008319793","journal-title":"J Clin Pharmacol"},{"issue":"Suppl 1","key":"2110_CR72","doi-asserted-by":"publisher","first-page":"3533","DOI":"10.1182\/blood.V130.Suppl_1.3533.3533","volume":"130","author":"RS Mittleman","year":"2017","unstructured":"Mittleman RS, Wilson P, Sykes K, Mihova M, Chickering JG, Ruff D, et al. Multiple-Ascending-Dose Study of the Soluble Guanylate Cyclase Stimulator, IW-1701, in Healthy Subjects. Blood. 2017;130(Suppl 1):3533. https:\/\/doi.org\/10.1182\/blood.V130.Suppl_1.3533.3533","journal-title":"Blood"},{"key":"2110_CR73","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1002\/cpdd.627","volume":"8","author":"JP Hanrahan","year":"2019","unstructured":"Hanrahan JP, Wakefield JD, Wilson PJ, Mihova M, Chickering JG, Ruff D, et al. A Randomized, Placebo-Controlled, Multiple-Ascending-Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Soluble Guanylate Cyclase Stimulator Praliciguat in Healthy Subjects. Clin Pharmacol Drug Dev. 2019;8:564\u201375. https:\/\/doi.org\/10.1002\/cpdd.627","journal-title":"Clin Pharmacol Drug Dev"},{"key":"2110_CR74","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1111\/cts.13537","volume":"16","author":"SJW van Kraaij","year":"2023","unstructured":"van Kraaij SJW, Gal P, Borghans LGJM, Klaassen ES, Dijkstra F, Winrow C, et al. First-in-human trial to assess safety, tolerability, pharmacokinetics, and pharmacodynamics of zagociguat (CY6463), a CNS-penetrant soluble guanylyl cyclase stimulator. Clin Transl Sci. 2023;16:1381\u201395. https:\/\/doi.org\/10.1111\/cts.13537","journal-title":"Clin Transl Sci"},{"key":"2110_CR75","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1177\/0091270008322906","volume":"48","author":"R Frey","year":"2008","unstructured":"Frey R, M\u00fcck W, Unger S, Artmeier-Brandt U, Weimann G, Wensing G. Pharmacokinetics, pharmacodynamics, tolerability, and safety of the soluble guanylate cyclase activator cinaciguat (BAY 58-2667) in healthy male volunteers. J Clin Pharmacol. 2008;48:1400\u201310. https:\/\/doi.org\/10.1177\/0091270008322906","journal-title":"J Clin Pharmacol"},{"key":"2110_CR76","doi-asserted-by":"publisher","first-page":"8101","DOI":"10.1007\/s00210-024-03165-w","volume":"397","author":"D Wong","year":"2024","unstructured":"Wong D, Seitz F, Bauer V, Giessmann T, Schulze F. Safety, tolerability, pharmacokinetics, and pharmacodynamics of BI 685509, a soluble guanylyl cyclase activator, in healthy volunteers: Results from two randomized controlled trials. Naunyn Schmiedebergs Arch Pharmacol. 2024;397:8101\u201316. https:\/\/doi.org\/10.1007\/s00210-024-03165-w","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"2110_CR77","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1007\/s00125-019-05062-x","volume":"63","author":"JP Hanrahan","year":"2020","unstructured":"Hanrahan JP, Seferovic JP, Wakefield JD, Wilson PJ, Chickering JG, Jung J, et al. An exploratory, randomised, placebo-controlled, 14 day trial of the soluble guanylate cyclase stimulator praliciguat in participants with type 2 diabetes and hypertension. Diabetologia. 2020;63:733\u201343. https:\/\/doi.org\/10.1007\/s00125-019-05062-x","journal-title":"Diabetologia"}],"container-title":["Hypertension Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41440-025-02110-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41440-025-02110-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41440-025-02110-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,6]],"date-time":"2025-04-06T22:04:39Z","timestamp":1743977079000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41440-025-02110-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,20]]},"references-count":77,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["2110"],"URL":"https:\/\/doi.org\/10.1038\/s41440-025-02110-5","relation":{},"ISSN":["0916-9636","1348-4214"],"issn-type":[{"value":"0916-9636","type":"print"},{"value":"1348-4214","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,20]]},"assertion":[{"value":"4 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 December 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 December 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}